Excelsior Biopharma (6496) - Net Assets
Based on the latest financial reports, Excelsior Biopharma (6496) has net assets worth NT$804.23 Million TWD (≈ $25.34 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.48 Billion ≈ $46.75 Million USD) and total liabilities (NT$679.78 Million ≈ $21.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Excelsior Biopharma tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$804.23 Million |
| % of Total Assets | 54.19% |
| Annual Growth Rate | -6.18% |
| 5-Year Change | -34.62% |
| 10-Year Change | N/A |
| Growth Volatility | 6.69 |
Excelsior Biopharma - Net Assets Trend (2017–2025)
This chart illustrates how Excelsior Biopharma's net assets have evolved over time, based on quarterly financial data. See 6496 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Excelsior Biopharma (2017–2025)
The table below shows the annual net assets of Excelsior Biopharma from 2017 to 2025. For live valuation and market cap data, see Excelsior Biopharma stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$804.23 Million ≈ $25.34 Million |
-18.88% |
| 2024-12-31 | NT$991.45 Million ≈ $31.24 Million |
-10.23% |
| 2023-12-31 | NT$1.10 Billion ≈ $34.80 Million |
-8.53% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.04 Million |
-1.85% |
| 2021-12-31 | NT$1.23 Billion ≈ $38.76 Million |
-4.12% |
| 2020-12-31 | NT$1.28 Billion ≈ $40.42 Million |
+2.25% |
| 2019-12-31 | NT$1.25 Billion ≈ $39.53 Million |
-8.62% |
| 2018-12-31 | NT$1.37 Billion ≈ $43.26 Million |
+2.49% |
| 2017-12-31 | NT$1.34 Billion ≈ $42.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Excelsior Biopharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 117.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$897.64 Million | 111.61% |
| Total Equity | NT$804.23 Million | 100.00% |
Excelsior Biopharma Competitors by Market Cap
The table below lists competitors of Excelsior Biopharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Change Financial Ltd
AU:CCA
|
$35.66 Million |
|
Milux Corporation Bhd
KLSE:7935
|
$35.70 Million |
|
Cipherlab Co Ltd
TWO:6160
|
$35.71 Million |
|
Biohit Oyj B
HE:BIOBV
|
$35.72 Million |
|
Simonds Group Ltd
AU:SIO
|
$35.65 Million |
|
Hi Sharp Electronics Co Ltd
TWO:3128
|
$35.63 Million |
|
Duxton Farms Ltd
AU:DBF
|
$35.62 Million |
|
Key Tronic Corporation
NASDAQ:KTCC
|
$35.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Excelsior Biopharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 991,450,000 to 804,232,000, a change of -187,218,000 (-18.9%).
- Net loss of 183,169,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-183.17 Million | -22.78% |
| Other Changes | NT$-4.05 Million | -0.5% |
| Total Change | NT$- | -18.88% |
Book Value vs Market Value Analysis
This analysis compares Excelsior Biopharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.85x to 1.41x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$28.71 | NT$24.30 | x |
| 2018-12-31 | NT$29.43 | NT$24.30 | x |
| 2019-12-31 | NT$26.89 | NT$24.30 | x |
| 2020-12-31 | NT$26.05 | NT$24.30 | x |
| 2021-12-31 | NT$26.45 | NT$24.30 | x |
| 2022-12-31 | NT$25.42 | NT$24.30 | x |
| 2023-12-31 | NT$23.11 | NT$24.30 | x |
| 2024-12-31 | NT$21.21 | NT$24.30 | x |
| 2025-12-31 | NT$17.27 | NT$24.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Excelsior Biopharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -20.39%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.85x
- Recent ROE (-22.78%) is below the historical average (0.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 20.87% | 16.30% | 1.02x | 1.25x | NT$145.70 Million |
| 2018 | 16.15% | 13.13% | 1.03x | 1.20x | NT$84.50 Million |
| 2019 | 5.66% | 4.61% | 1.03x | 1.19x | NT$-54.47 Million |
| 2020 | 2.75% | 2.45% | 0.76x | 1.48x | NT$-93.01 Million |
| 2021 | -1.27% | -1.17% | 0.73x | 1.49x | NT$-138.66 Million |
| 2022 | -2.80% | -5.03% | 0.39x | 1.42x | NT$-154.50 Million |
| 2023 | -8.24% | -11.80% | 0.49x | 1.43x | NT$-201.46 Million |
| 2024 | -9.96% | -11.45% | 0.55x | 1.59x | NT$-197.85 Million |
| 2025 | -22.78% | -20.39% | 0.61x | 1.85x | NT$-263.59 Million |
Industry Comparison
This section compares Excelsior Biopharma's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,032,347,900
- Average return on equity (ROE) among peers: 4.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Excelsior Biopharma (6496) | NT$804.23 Million | 20.87% | 0.85x | $35.66 Million |
| Grape King Bio Ltd (1707) | $1.74 Billion | 9.43% | 0.48x | $462.98 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $3.12 Billion | 7.90% | 0.56x | $352.43 Million |
| Maywufa Co Ltd (1731) | $1.47 Billion | 5.23% | 0.78x | $90.87 Million |
| ScinoPharm Taiwan Ltd (1789) | $8.56 Billion | 11.21% | 0.11x | $499.50 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $1.49 Billion | 0.80% | 0.34x | $1.58 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $44.35 Million |
| LIWANLI Innovation Co Ltd (3054) | $1.51 Billion | 4.15% | 0.15x | $172.02 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $478.34 Million |
| TTY Biopharm Co Ltd (4105) | $5.77 Billion | 14.42% | 0.61x | $577.35 Million |
| Phytohealth Corp (4108) | $1.56 Billion | -10.88% | 0.06x | $75.40 Million |
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more